Wanbury Ltd. net profit up 696% (YOY) at Rs. 8.3 cr in Q4FY24
Wanbury Ltd., one of India’s fastest growing pharmaceutical company having a presence in API global market and domestic branded Formulation, announced its financial results for the fourth quarter and year ended March 31, 2024. Consolidated Q4
Wanbury Ltd., one of India’s fastest growing pharmaceutical company having a presence in API global market and domestic branded Formulation, announced its financial results for the fourth quarter and year ended March 31, 2024.
Consolidated Q4 & FY24 Financial Highlights
(Rs in Crore)
| Particulars | Q4 FY24 | Q3 FY24 | % QoQ | Q4 FY23 | % YoY | FY24 | FY23 | % YoY |
| Revenue from Operations | 139.4 | 145.5 | -4.2% | 133.0 | 4.8% | 575.6 | 499.6 | 15.2% |
| EBITDA | 19.1 | 21.8 | -13% | 12.1 | 57.7% | 73.0 | 24.1 | 203.1% |
| EBITDA Margin (%) | 13.7% | 15.0% | -1.3% | 9.1% | 4.5% | 12.7% | 4.8% | 7.9% |
| PAT | 8.3 | 10.3 | -18.6% | 1.0 | 696% | 30.4 | (10.4) | 392.4% |
| PAT Margin (%) | 6.0% | 7.0% | -1% | 0.8% | 5.2% | 5.3% | (2.1%) | 7.3% |
Commenting on the performance, Mr Mohan Rayana, Director, Wanbury Ltd. said, “The company registered a 15% growth in revenue & four-fold jump in its net profits on YOY basis. The company has achieved the same through growth in sales of its key products Metformin & Sertraline. The company has also undertook various measures to improve its profitability like focus on niche products, cost optimisation via operational excellence, yield improvement, etc.
The management is confident of continuing this growth journey in coming quarters through expansion of customer base & increase in SOB of existing customers coupled with development of new APIs and entry into new therapy segment in Formulation business.”
